Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period

Arthritis Care and Research

Volumn 68, Issue 7, 2016, Pages 981-987

  Medina Quiñones, Carmen V ^a   Ramos Merino, Lucía ^b   Ruiz Sada, Pablo ^c   Isenberg, David ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; COMPLEMENT COMPONENT C3; CORTICOSTEROID; DOUBLE STRANDED DNA; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; REMISSION; SCORING SYSTEM; SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT DISEASE; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84976565546     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22774     Document Type: Article

References (22)

1. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009;48:673–5.
2. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus. Am J Med 1979;66:210–5.
3. Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:900–4.
4. Gladman DD, Goldsmith CG, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468–71.
5. Liang MH, Socher SA, Larsen MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107–18.
6. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
7. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. JAMA 1964;190:104–11.
8. Tozman EC, Urowitz MB, Gladman DD. Prolonged complete remission in previously severe SLE. Ann Rheum Dis 1982;41:39–40.
9. Formiga F, Moga I, Pac M, Mitjavila F, Rivera A, Pujol R. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Rheumatology (Oxford) 1999;38:724–7.
10. Drenkard C, Villa AR, Garcia-Padilla A, Perez-Vazquez ME, Alarcon-Segovia D. Remission of systemic lupus erythematosus. Medicine (Baltimore) 1996;75:88–99.
11. Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol 1985;12:916–8.
12. Urowitz MB, Feletar M, Bruce IN, Ibanez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005;32:1467–72.
13. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al, and the Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998;7:80–5.
14. Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al, and the LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168–72.
15. Steiman AJ, Gladman DD, Ibanez D, Urowitz MB. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken) 2012;64:511–8.
16. Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus recommendations from an international task force. Ann Rheum Dis 2014;73:958–67.
17. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447–58.
18. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003;42:1372–9.
19. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44;902–6.
20. Nossent JC. SLICC/ACR damage index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol 1998;25:654–9.
21. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford) 2012;51:491–8.
22. Cooper GS, Treadwell EL, St.Clair EW, Gilkeson GS, Dolley MA. Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus. Arthritis Rheum 2007;57:993–9.